Hip fracture lower limb deep vein thrombosis
Conditions
Interventions
Liposomal bupivacaine group:Participants immediately received ultrasound-guided perineural nerve block on the affected side after admission, using 20mL of liposomal bupivacaine (266mg).All patients re
Sham control group:Participants immediately received ultrasound-guided pericapsular nerve group block on the affected side after admission, using 20mL of saline.All patients received intravenous non-s
Sponsors
Shunde Hospital of Guangzhou University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with hip fractures, including femoral neck fractures and intertrochanteric fractures. 2. Age >= 65 years. 3. 18 kg/m^2 <= BMI <= 30 kg/m^2. 4. American Society of Anesthesiologists classification of I-III. 5. Voluntarily signed informed consent form.
Exclusion criteria
Exclusion criteria: 1. Composite injury: Multiple fractures combined, such as trauma in areas other than the hip fracture. 2. Positive ultrasound examination for bilateral lower limb deep vein thrombosis with obstructed forward movement. 3. Contraindications related to LB: History of liposome allergy, history of allergy to local anesthetics (including bupivacaine, ropivacaine, and their derivatives), and severe cardiovascular and respiratory dysfunction. 4. Contraindications related to nerve block: Infection at the puncture site, abnormal nerve function in the lower limbs, and local or systemic infection. 5. Time from injury to hospitalization > 24 hours. 6. Patients with severe liver and kidney dysfunction. 7. Patients with a history of drug addiction or abuse. 8. MMSE score less than 26 points. 9. History of old lower limb deep vein thrombosis. 10. Patients with coagulation dysfunction. 11. Patients taking anticoagulant medications. 12. Patients with an electrocardiogram showing a ventricular rate of less than 50 beats per minute or prolonged Q-T interval. 13. Patients with blood-related diseases or other conditions requiring transfusion. 14. Patients participating in other clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of deep vein thrombosis in both lower extremities; | — |
Secondary
| Measure | Time frame |
|---|---|
| Function-based pain assessment;The situation regarding opioid remedies(The initial analgesic remedial time and total remedial volume).;Perioperative stress levels (IL1, IL6, C-reactive protein, procalcitonin, interferon a),;Perioperative thrombosis-related indicators (MPO-DNA complex, citrulline histone H3, D-dimer);The adverse events related to this study (such as blockade operations, bupivacaine liposome, and opioids, etc.);Preoperative waiting time;Length of hospital stay;Total expenses during hospitalization; | — |
Countries
China
Contacts
Public ContactHaobin Peng
Shunde Hospital of Guangzhou University of Traditional Chinese Medicine
Outcome results
None listed